System will benefit in vitro investigation of T cell functions and research into adoptive T cell immunotherapy
Dynal Biotech has launched an innovative new range of easy-to-use products called Dynabeads Tcap.
This is said to be the only ready-to-use system to use proven magnetic bead technology to isolate a high yield of antigen-specific CD8+ T cells.
It will benefit in vitro investigation of T cell functions and research into adoptive T cell immunotherapy.
Dynabeads Tcap for Epstein Barr virus, cytomegalovirus and a range of cancer antigens are available now - the range will be further developed in the coming year.
Dynabeads Tcap are coupled with recombinant HLA-A*0201 molecules loaded with specific peptides which are recognised by CD8+ T cells.
After a short, tube-based incubation with Dynabeads Tcap, antigen specific CD8+ T cells are captured and isolated with a magnet.
The process is quick, reliable and efficient.
The isolated cells are pure and viable and can be expanded in culture.
Dynabeads are monosized, superparamagnetic microbeads that are coated with a variety of ligands, depending on the target of interest.
The beads bind to the target of interest and when a magnet is applied, the bead-target complex moves towards the magnet.
This proven technology is widely used in cell biology, immunology, molecular biology and microbiology.
